Mimedx (MDXG) Non-Current Assets (2010 - 2026)
Mimedx (MDXG) reported Non-Current Assets of $68.4 million for Q1 2026, down 2.78% on a YoY basis from $70.3 million in Q1 2025, and up 4.86% sequentially from $65.2 million in Q4 2025.
Mimedx (MDXG) Non-Current Assets (2010 - 2026) Analysis & Trends
Mimedx (MDXG) has 17 years of Non-Current Assets data on file, last reported at $68.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 2.78% year-over-year to $68.4 million; the trailing twelve-month figure through Mar 2026 stood at $268.7 million (down 7.44% YoY), and the FY2025 full-year result was $65.2 million, down 9.51% from the prior year.
- Non-Current Assets advanced to $68.4 million in Q1 2026, from $65.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $82.8 million in Q1 2024 to a low of $34.5 million in Q3 2023.
- A 5-year average of $57.2 million and a median of $65.2 million in 2025 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets jumped 127.19% in 2024 and retreated 15.12% in 2025, its largest moves.
- Tracing MDXG's Non-Current Assets over 5 years: stood at $37.2 million in 2022, then jumped by 100.86% to $74.8 million in 2023, then retreated by 3.69% to $72.0 million in 2024, then dropped by 9.51% to $65.2 million in 2025, then gained by 4.86% to $68.4 million in 2026.
- Business Quant data shows MDXG's Non-Current Assets at $68.4 million in Q1 2026, $65.2 million in Q4 2025, and $64.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Mimedx | 615.09 Mn | 455.31 Mn | 41.62 Mn | 68.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.35 Mn |
| Dec 31, 2025 | 65.18 Mn |
| Sep 30, 2025 | 64.89 Mn |
| Jun 30, 2025 | 70.23 Mn |
| Mar 31, 2025 | 70.31 Mn |
| Dec 31, 2024 | 72.03 Mn |
| Sep 30, 2024 | 71.75 Mn |
| Jun 30, 2024 | 76.17 Mn |
| Mar 31, 2024 | 82.83 Mn |
| Dec 31, 2023 | 74.79 Mn |
| Sep 30, 2023 | 34.52 Mn |
| Jun 30, 2023 | 35.16 Mn |
| Mar 31, 2023 | 36.46 Mn |
| Dec 31, 2022 | 37.23 Mn |
| Sep 30, 2022 | 36.76 Mn |
| Jun 30, 2022 | 37.66 Mn |
| Mar 31, 2022 | 38.54 Mn |
| Dec 31, 2021 | 39.41 Mn |
| Sep 30, 2021 | 38.62 Mn |
| Jun 30, 2021 | 39.46 Mn |